Antidepressant Cymbalta approved for treating diabetic peripheral neuropathic pain
Main Category: Pain / AnestheticsArticle Date: 08 Sep 2004 - 7:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
4.33 (3 votes) |
| Healthcare Prof: |  |
The FDA has approved the use of an antidepressant for the treatment of diabetic pain - pain associated with nerve damage suffered by diabetic patients. This is the first drug to be approved for the treatment of diabetic peripheral neuropathic pain.
The drug, Cymbalta, is produced by Eli Lilly.
This is a double whammy for Cymbalta. Last month it was approved as an antidepressant (for treating major depression).
In the USA 5 million patients suffer from diabetic peripheral neuropathic pain.
Business experts say the income potential for Eli Lilly is enormous. Some say Cymbalta's income for the treatment of diabetic peripheral neuropathic pain should top the $1bn mark. Add to that another three to four billion for treating depression and you have a blockbuster.
http://www.cymbalta.com
Visit our pain / anesthetics section for the latest news on this subject.
MLA
11 Feb. 2012. <http://www.medicalnewstoday.com/releases/13054.php>
APA
http://www.medicalnewstoday.com/releases/13054.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
